Search research articles
Contact Us
Filters
Showing results (71-80 of 241) with videos related to
Page
of 25
Sort By:
The American Journal of Bioethics : AJOB
|
September 20, 2008
Hidden sources of private industry funding
David B Resnik
Contemporary Clinical Trials
|
November 4, 2008
Do informed consent documents matter?
David B Resnik
Science and Engineering Ethics
|
November 14, 2008
What is "dual use" research? A response to Miller and Selgelid
David B Resnik
Accountability in Research
|
September 13, 2007
Intentional exposure studies of environmental agents on human subjects: assessing benefits and risks
David B Resnik
The Hastings Center Report
|
April 11, 2021
Public Engagement and the Social Risks of Science
David B Resnik
Monitor (Associates of Clinical Pharmacology)
|
April 17, 2015
Postmarketing Research and Surveillance: Issues and Challenges
David B Resnik
Health Policy (Amsterdam, Netherlands)
|
July 10, 2003
Are DNA patents bad for medicine?
David B Resnik
Accountability in Research
|
October 21, 2011
Disclosure of individualized research results: a precautionary approach
David B Resnik
Accountability in Research
|
January 17, 2019
Is it time to revise the definition of research misconduct?
David B Resnik
The Hastings Center Report
|
December 27, 2018
Difficulties with Applying a Strong Social Value Requirement to Clinical Research
David B Resnik
Page
of 25
Search research articles
Search
Showing results (71-80 of 241) with videos related to
Sort By:
Page
of 25
The American Journal of Bioethics : AJOB
|
September 20, 2008
Hidden sources of private industry funding
David B Resnik
Contemporary Clinical Trials
|
November 4, 2008
Do informed consent documents matter?
David B Resnik
Science and Engineering Ethics
|
November 14, 2008
What is "dual use" research? A response to Miller and Selgelid
David B Resnik
Accountability in Research
|
September 13, 2007
Intentional exposure studies of environmental agents on human subjects: assessing benefits and risks
David B Resnik
The Hastings Center Report
|
April 11, 2021
Public Engagement and the Social Risks of Science
David B Resnik
Monitor (Associates of Clinical Pharmacology)
|
April 17, 2015
Postmarketing Research and Surveillance: Issues and Challenges
David B Resnik
Health Policy (Amsterdam, Netherlands)
|
July 10, 2003
Are DNA patents bad for medicine?
David B Resnik
Accountability in Research
|
October 21, 2011
Disclosure of individualized research results: a precautionary approach
David B Resnik
Accountability in Research
|
January 17, 2019
Is it time to revise the definition of research misconduct?
David B Resnik
The Hastings Center Report
|
December 27, 2018
Difficulties with Applying a Strong Social Value Requirement to Clinical Research
David B Resnik
Page
of 25